"NIH licenses its patents to enable the private sector to develop diagnostics, therapeutics, and devices that improve public health," said National Institutes of Health Director Francis S. Collins, MD, PhD. "We want to ensure that our biological materials and patents covering treatments or vaccines for neglected tropical diseases, as with all diseases, are available as broadly as possible to speed the development of new products for people who are most burdened by these diseases, and WIPO Re:Search helps us to do this."
The founding eight pharmaceutical companies, WIPO, BVGH, and NIH are joined by a distinguished group of globally recognized institutions as providers, potential users, and supporters of WIPO Re:Search (see annex). BVGH will manage the WIPO Re:Search Partnership Hub, which will facilitate relationships between the pharmaceutical company providers and new users.
"In our role as administrator of the WIPO Re:Search Partnership Hub, BIO Ventures for Global Health is excited to bring these new opportunities to neglected disease researchers around the world to accelerate their work in this area of critical unmet need," said Don Joseph, Chief Operating Officer of BVGH. "As both present and future providers evaluate their internal data and IP with the goal to provide focused information which they believe will best serve the neglected tropical disease research and development community, WIPO Re:Search will build on previous R&D investments to speed the development of drugs, vaccines, and diagnostics for the neglected diseases that disproportionately impact people living in resource-poor countrie
|SOURCE BIO Ventures for Global Health|
Copyright©2010 PR Newswire.
All rights reserved